Bortezomib-Based Salvage Chemotherapy in Refractory/Relapsed Multiple Myeloma Patients: A Single Center Experience in Real Clinical Practice.
10.3904/kjm.2015.88.5.537
- Author:
Dong Hyun KIM
1
;
Ji Hyun LEE
;
Sung Hyun KIM
;
Sung Yong OH
;
Suee LEE
;
Sang Yi MOON
;
Hyo Jin KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. kimhj@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Multiple myeloma;
Bortezomib;
Salvage therapy
- MeSH:
Dexamethasone;
Drug Therapy*;
Follow-Up Studies;
Herpes Zoster;
Humans;
Incidence;
Mortality;
Multiple Myeloma*;
Neutropenia;
Peripheral Nervous System Diseases;
Recurrence;
Retrospective Studies;
Salvage Therapy;
Thrombocytopenia
- From:Korean Journal of Medicine
2015;88(5):537-546
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Bortezomib-based chemotherapy has proven to be an effective salvage regimen for refractory/relapsed multiple myeloma patients in many clinical trials. However, few reports have shown the outcomes and adverse events of bortezomib-based salvage chemotherapy in clinical practice. METHODS: From April 2006 to September 2011, 37 patients were retrospectively analyzed. A total of 19 patients received bortezomib therapy and 18 patients received bortezomib plus dexamethasone therapy. RESULTS: The median follow-up duration was 18.13 months (range, 0.97-87.20 months). The median number of cycles administered was four (range, 1-13). The overall response rate by International Myeloma Working Group (IMWG) 2006 criteria was 64.9%, including six complete responses (16.2%). The median number of cycles to best response was three (95% confidence interval [CI], 1.36-4.64). Six patients achieved their best responses after four cycles of bortezomib therapy. The median time to progression and overall survival were 5.10 (95% CI 4.03-6.17), and 23.10 (95% CI, 9.24-36.96) months, respectively. The incidence of grade 3/4 neutropenia and thrombocytopenia was 29.7% and 64.9%, respectively. A total of 27.0% patients experienced grade 3 peripheral neuropathy. Herpes zoster developed in 11 patients (29.7%). Treatment was stopped in 22 patients (59.5%) due to adverse events after bortezomib-based therapy, and treatment-related mortality occurred in 4 of 25 deaths in total. CONCLUSIONS: Bortezomib-based therapy is a very effective salvage regimen in real clinical practice, although patients relapse after multiple chemotherapies. Despite intolerable in some patients, management of toxicities and extended cycles of therapy could benefit more patients, resulting in higher response rates.
